The National Cancer Institute (NCI) has designated 40 cancer centers throughout the United States as "Comprehensive" centers. These elite centers have been recognized for their focus on scientific excellence and have dedicated themselves to the prevention, treatment and cure of cancer, including malignant mesothelioma. Following is a list of Cancer Centers by state.

Alabama

UAB Comprehensive Cancer Center
1802 6th Avenue, S.
Birmingham, AL 35294
Request an appointment: (800) UAB-0933 or (205) 975-8222

Arizona

Arizona Cancer Center
1515 N. Campbell Avenue
Tucson, AZ 85724
Request an appointment: (520) 626-2900

California

City of Hope National Medical Center
1500 E. Duarte Road
Duarte, CA 91010
Request an appointment: (866) 434-HOPE (4673)

University of California, San Diego (UCSD) Moores Cancer Center
3855 Health Sciences Drive
La Jolla, CA 92093
Request an appointment: (866) 773-2703 or (858) 822-6200

UCLA Jonsson Comprehensive Cancer Center
10833 Le Conte Avenue
Los Angeles, CA 90095
Request an appointment: (800) 825-2631

USC/Norris Comprehensive Cancer Center
1441 Eastlake Avenue
Los Angeles, CA 90033
Request an appointment: (800) USC-CARE

University of California, Irvine (UCI) Chao Family Comprehensive Cancer Center
101 The City Drive, S.
Orange, CA 92868
Request an appointment: (877) UCI-DOCS (824-3627)

University of California, San Francisco (UCSF) Comprehensive Cancer Center
1600 Divisadero Street
San Francisco, CA 94115
Request an appointment: (888) 689-8273 or (415) 885-7777

Stanford University Comprehensive Cancer Center
875 Blake Wilbur Drive
Stanford, CA 94305
Request an appointment: (650) 498-6000

Colorado

University of Colorado Cancer Center
1665 N. Ursula Street
Aurora, CO 80045
Request an appointment: (800) 473-2288 or (720) 848-0300

Connecticut

Yale Cancer Center
15 York Street
New Haven, CT 06510
Request an appointment: (203) 785-4191

District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University
3800 Reservoir Road, NW
Washington, DC 20007
Request an appointment: (202) 444-2223

Florida

H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, FL 33612
Request an appointment: (888) 860-2778 or (813) 979-3980

Illinois

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Galter Pavilion
675 N. St. Clair, 21st Floor
Chicago, IL 60611
Request an appointment: (866) LURIE-CC (587-4322)

Iowa

University of Iowa Holden Comprehensive Cancer Center
200 Hawkins Drive
Iowa City, IA 52242
Request an appointment: (319) 356-4200 8:00 am - 5:00 pm (M-F)
(800) 777-8442 or
(319) 384-8442 (After hours)

Maryland

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
401 N. Broadway
Baltimore, MD 21231
Request an appointment: (410) 955-5222

Massachusetts

Dana-Farber Cancer Institute
44 Binney Street
Boston, MA 02115
Request an appointment: (877) 332-4294

Michigan

University of Michigan Comprehensive Cancer Center
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Request an appointment: (800) 865-1125

Barbara Ann Karmanos Cancer Institute
4100 John R
Detroit, MI 48201
Request an appointment: (800) KARMANOS (527-6266)

Minnesota

University of Minnesota Cancer Center
425 E. River Road
Minneapolis, MN 55455
Request an appointment: (888) CANCER MN (226-2376)
(Toll Free in IA, MN, ND, SD, WI)
(612) 624-2620 (Outside Area)

Mayo Clinic Cancer Center
200 First Street, SW
Rochester, MN 55905
Request an appointment: (507) 538-3270

Missouri

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
660 S. Euclid Avenue
St. Louis, MO 63110
Request an appointment: (877) 251-6485 or (314) 747-3046

New Hampshire

Norris Cotton Cancer Center
One Medical Center Drive
Lebanon, NH 03756
Request an appointment: (603) 653-9000

New Jersey

Cancer Hospital of New Jersey at Robert Wood Johnson University Hospital
195 Little Albany Street
New Brunswick, NJ 08903
Request an appointment: (732) 828-3000

New York

Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263
Request an appointment: (800) ROSWELL (767-9355)

Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Request an appointment: (800) 525-2225

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Avenue
New York, NY 10032
Request an appointment: (877) NYP-WELL (697-9355)

North Carolina

University of North Carolina (UNC) Lineberger Comprehensive Cancer Center
450 West Drive
Chapel Hill, NC 27599
Request an appointment: (866) 828-0270

Duke Comprehensive Cancer Center
2424 Erwin Road
Durham, NC 27705
Request an appointment: (888) ASK-DUKE (275-3853)

Wake Forest University Comprehensive Cancer Center
Medical Center Boulevard
Winston-Salem, NC 27157
Request an appointment: (800) 446-2255 or (336) 716-2255

Ohio

Case Comprehensive Cancer Center, Ireland Cancer Center
11100 Euclid Avenue
Cleveland, OH 44106
Request an appointment: (800) 641-2422

Comprehensive Cancer Center - Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
300 W. 10th Avenue
Columbus, OH 43210
Request an appointment: (800) 293-5066 or (614) 293-5066

Pennsylvania

Abramson Cancer Center of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Request an appointment: (800) 789-PENN (7366)

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Request an appointment: (215) 728-2570

University of Pittsburgh Cancer Institute
5150 Centre Avenue
Pittsburgh, PA 15232
Request an appointment: (412) 647-2811

Tennessee

Vanderbilt-Ingram Cancer Center
691 Preston Building
Nashville, TN 37232
Request an appointment: (800) 811-8480

Texas

University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Request an appointment: (800) 392-1611 or (713) 792-6161

Vermont

Vermont Cancer Center at the University of Vermont
89 Beaumont Avenue
Burlington, VT 05405
Request an appointment: (802) 656-4414

Washington

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue, N.
Seattle, WA 98109
Request an appointment: (800) 804-8824 or (206) 288-1024

Wisconsin

University of Wisconsin Comprehensive Cancer Center
600 Highland Avenue
Madison, WI 53792
Request an appointment: (800) 622-8922

NATIONAL CANCER INSTITUTE CANCER CENTERS

UC Davis Cancer Center
4501 X Street
Sacramento, CA 95817
Request an appointment: (800) 362-5566 or (916) 734-5900

University of Chicago Hospitals
5841 S. Maryland Avenue
Chicago, IL 60637
Request an appointment: (888) UCH-0200

NYU Cancer Institute
550 First Avenue
New York, NY 10016
Request an appointment: (888) 7-NYU-MED (769-8633)

The Cleveland Clinic, Taussig Cancer Center
9500 Euclid Avenue
Cleveland, OH 44195
Request an appointment: (866) 320-4573 or (216) 444-5501

National Institutes of Health (NIH) Clinical Center, Bethesda, MD
National Insitutes of Health
10 Center Dr.
Bethesda, MD 20892
Request an appointment: 301-496-2626

Treatment of malignant mesothelioma using conventional therapies in combination with radiation and or chemotherapy on stage I or II Mesothelioma have proved on average 74.6 percent successful in extending the patient's life span by five years or more [commonly known as remission][this percentage may increase or decrease depending on date of discovery / stage of malignant development] (Oncology Today, 2009). Treatment course is primarily determined by the staging or development. This is unlike traditional treatment such as surgery by itself which has proved only be 16.3 percent likely to extend a patient's life span by five years or more [commonly known as remission]. Clinical behavior of the malignancy is affected by several factors including the continuous mesothelial surface of the pleural cavity which favors local metastasis via exfoliated cells, invasion to underlying tissue and other organs within the pleural cavity, and the extremely long latency period between asbestos exposure and development of the disease.

Surgery~Treatment of Mesothelioma

Surgery, by itself, has proved disappointing. However, research indicates varied success when used in combination with radiation and chemotherapy (Duke, 2008) A pleurectomy/decortication is the most common surgery, in which the lining of the chest is removed. Less common is an extrapleural pneumonectomy (EPP), in which the lung, lining of the inside of the chest, the hemi-diaphragm and the pericardium are removed.

Radiation~Treatment of Mesothelioma

For patients with localized disease, and who can tolerate a radical surgery, radiation is often given post-operatively as a consolidative treatment. The entire hemi-thorax is treated with radiation therapy, often given simultaneously with chemotherapy. This approach of using surgery followed by radiation with chemotherapy has been pioneered by the thoracic oncology team at Brigham & Women's Hospital in Boston. Delivering radiation and chemotherapy after a radical surgery has led to extended life expectancy in selected patient populations with some patients surviving more than 5 years. As part of a curative approach to mesothelioma, radiotherapy is also commonly applied to the sites of chest drain insertion, in order to prevent growth of the tumor along the track in the chest wall.

Although mesothelioma is generally resistant to curative treatment with radiotherapy alone, palliative treatment regimens are sometimes used to relieve symptoms arising from tumor growth, such as obstruction of a major blood vessel. Radiation therapy when given alone with curative intent has never been shown to improve survival from mesothelioma. The necessary radiation dose to treat mesothelioma that has not been surgically removed would be very toxic.

Chemotherapy~Treatment of Mesothelioma

Chemotherapy is the only treatment for mesothelioma that has been proven to improve survival in randomised and controlled trials. The landmark study published in 2003 by Vogelzang and colleagues compared cisplatin chemotherapy alone with a combination of cisplatin and pemetrexed (brand name Alimta) chemotherapy) in patients who had not received chemotherapy for malignant pleural mesothelioma previously and were not candidates for more aggressive "curative" surgery. This trial was the first to report a survival advantage from chemotherapy in malignant pleural mesothelioma, showing a statistically significant improvement in median survival from 10 months in the patients treated with cisplatin alone to 13.3 months in the combination pemetrexed group in patients who received supplementation with folate and vitamin B12. Vitamin supplementation was given to most patients in the trial and pemetrexed related side effects were significantly less in patients receiving pemetrexed when they also received daily oral folate 500mcg and intramuscular vitamin B12 1000mcg every 9 weeks compared with patients receiving pemetrexed without vitamin supplementation. The objective response rate increased from 20% in the cisplatin group to 46% in the combination pemetrexed group. Some side effects such as nausea and vomiting, stomatitis, and diarrhoea were more common in the combination pemetrexed group but only affected a minority of patients and overall the combination of pemetrexed and cisplatin was well tolerated when patients received vitamin supplementation; both quality of life and lung function tests improved in the combination pemetrexed group. In February 2004, the United States Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma. However, there are still unanswered questions about the optimal use of chemotherapy, including when to start treatment, and the optimal number of cycles to give.

Cisplatin in combination with raltitrexed has shown an improvement in survival similar to that reported for pemetrexed in combination with cisplatin, but raltitrexed is no longer commercially available for this indication. For patients unable to tolerate pemetrexed, cisplatin in combination with gemcitabine or vinorelbine is an alternative, or vinorelbine on its own, although a survival benefit has not been shown for these drugs. For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.

In January 2009, the United States FDA approved using conventional therapies such as surgery in combination with radiation and or chemotherapy on stage I or II Mesothelioma after research conducted by a nationwide study by Duke University concluded an almost 50 point increase in remission rates.

Immunotherapy~Treatment of Mesothelioma

Treatment regimens involving immunotherapy have yielded variable results. For example, intrapleural inoculation of Bacillus Calmette-Guérin (BCG) in an attempt to boost the immune response, was found to be of no benefit to the patient (while it may benefit patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients undergoing this particular therapy experienced major side effects. Indeed, this trial was suspended in view of the unacceptably high levels of IL-2 toxicity and the severity of side effects such as fever and cachexia. Nonetheless, other trials involving interferon alpha have proved more encouraging with 20% of patients experiencing a greater than 50% reduction in tumor mass combined with minimal side effects.

Heated Intraoperative Intraperitoneal Chemotherapy

A procedure known as heated intraoperative intraperitoneal chemotherapy was developed by Paul Sugarbaker at the Washington Cancer Institute. The surgeon removes as much of the tumor as possible followed by the direct administration of a chemotherapy agent, heated to between 40 and 48°C, in the abdomen. The fluid is perfused for 60 to 120 minutes and then drained.

This technique permits the administration of high concentrations of selected drugs into the abdominal and pelvic surfaces. Heating the chemotherapy treatment increases the penetration of the drugs into tissues. Also, heating itself damages the malignant cells more than the normal cells.

Stages of mesothelioma is based on the recommendation by the International Mesothelioma Interest Group. TNM classification of the primary tumor, lymph node involvement, and distant metastasis is performed. Mesothelioma is staged Ia–IV (one-A to four) based on the TNM status.Staging is based on a knowledge of how the cancer develops, from the primary tumor, to the invasion of nearby organs and tissues, to distant spread or metastasis. Staging systems have evolved over time, and they continue to change as scientists learn more about cancer. Some staging systems cover many different types of cancer, while others focus on more specific cancers. The TNM (primary tumor, regional lymph nodes, distant metastasis) is the most common staging system for mesothelioma.Treatment options are often determined by the stage of mesothelioma a patient is in. There are three staging systems currently in use for pleural mesothelioma and each one measures somewhat different variables; peritoneal mesothelioma is not staged.

Some elements common to most staging systems are:

• Location of the primary tumor.
• Size and number of the tumors.
• Lymph node involvement.
• Cell type and tumor grade.
• Metastasis.

Many cancer registries, such as the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) use summary staging, a system used for all types of cancer. Summary staging groups cancer into five main categories:

• In situ - cancer that is present only in the layer of cells in which it began.
• Localized - cancer that is limited to the organ in which it began with no evidence of spread.
• Regional - cancer that has spread from the primary site to nearby lymph nodes or organs.
• Distant - cancer that has spread from the primary site to distant lymph nodes or organs.
• Unknown - cases where not enough information exists to indicate stage.

Several types of testing may be used to help doctors determine stage, and to formulate a treatment plan.

• Physical examinations. The doctor examines the body by looking, feeling and listening to anything out of the ordinary.
• Imaging techniques. Procedures such as x-rays, CT scans, MRIs and PET scans may show the location, size of the tumor and whether the cancer has spread.
• Laboratory tests. Studies of blood, urine, fluid and tissue can provide information about the cancer. Tumor markers, sometime elevated when cancer is present, may provide information.
• Pathology reports. Results of the examination of tissue samples can include information about the size of the tumor(s), extension into adjacent structures, type of cells and grade of the tumor. Results of the examination of cells in fluid, such as that from a mesothelioma-related pleural effusion, may also provide information.
• Surgical reports. Observations about the size and appearance of the tumor(s), lymph nodes and nearby organs.

Staging information should be provided to the patient by his doctor so that potential treatment plans can be discussed. Stage of the mesothelioma, as well as consideration of other factors such as age, health status and the patient's wishes may dictate different treatment options.

The oldest staging system and the one most often used is the Butchart System which is based mainly on the extent of primary tumor mass and divides mesotheliomas into four stages. The more recent TNM system considers variables of tumor in mass and spread, lymph node involvement, and metastasis. The Brigham System is the latest system and stages mesothelioma according to resectability (the ability to surgically remove) and lymph node involvement.

Butchart System – extent of primary tumor mass

• Stage I: Mesothelioma is present in the right or left pleura and may also involve the diaphragm on the same side.
• Stage II: Mesothelioma invades the chest wall or involves the esophagus, heart, or pleura on both sides. Lymph nodes in the chest may also be involved.
• Stage III: Mesothelioma has penetrated through the diaphragm into the lining of the abdominal cavity or peritoneum. Lymph nodes beyond those in the chest may also be involved.
• Stage IV: There is evidence of metastasis or spread through the bloodstream to other organs.

TNM System -- variables of T (tumor), N (lymph nodes), M (metastasis)

• Stage I: Mesothelioma involves right or left pleura and may also have spread to the lung, pericardium, or diaphragm on the same side. Lymph nodes are not involved.
• Stage II: Mesothelioma has spread from the pleura on one side to nearby lymph nodes next to the lung on the same side. It may also have spread into the lung, pericardium, or diaphragm on the same side.
• Stage III: Mesothelioma is now in the chest wall, muscle, ribs, heart, esophagus, or other organs in the chest on the same side with or without spread to lymph nodes on the same side as the primary tumor.
• Stage IV: Mesothelioma has spread into the lymph nodes in the chest on the side opposite the primary tumor, or extends to the pleura or lung on the opposite side, or directly extends into organs in the abdominal cavity or neck. Any distant metastases is included in this stage.

Brigham System: (variables of tumor resectability and nodal status)

• Stage I: Resectable mesothelioma and no lymph node involvement
• Stage II: Resectable mesothelioma but with lymph node involvement
• Stage III: Unresectable mesothelioma extending into chest wall, heart, or through diaphragm, peritoneum; with or without extrathoracic lymph node involvement
• Stage IV: Distant metastatic disease

Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos.The early symptoms of mesothelioma are generally non-specific, and may lead to a delay in diagnosis. Sometimes resembling viral pneumonia, pleural mesothelioma patients may present with shortness of breath, chest pain and/or persistent cough; some patients show no symptoms at all. A chest x-ray may show a build-up of fluid or pleural effusion (discussed below). The right lung is affected 60% of the time, with involvement of both lungs being seen in approximately 5% of patients at the time of diagnosis. Less common symptoms of pleural mesothelioma include fever, night sweats and weight loss. Symptoms of peritoneal mesothelioma may include pain or swelling in the abdomen due to a build-up of fluid, nausea, weight loss, bowel obstruction, anemia or swelling of the feet.
Shortness of breath, cough, and pain in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma.

Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and pain due to ascites (a buildup of fluid in the abdominal cavity). Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. If the cancer has spread beyond the mesothelium to other parts of the body, symptoms may include pain, trouble swallowing, or swelling of the neck or face.

These symptoms may be caused by mesothelioma or by other, less serious conditions.

Mesothelioma that affects the pleura can cause these signs and symptoms:

• Chest wall pain
• Pleural effusion, or fluid surrounding the lung
• Shortness of breath
• Fatigue or anemia
• Wheezing, hoarseness, or cough
• Blood in the sputum (fluid) coughed up (hemoptysis)

In severe cases, the person may have many tumor masses. The individual may develop a pneumothorax, or collapse of the lung. The disease may metastasize, or spread, to other parts of the body.

Tumors that affect the abdominal cavity often do not cause symptoms until they are at a late stage. Symptoms include:

• Abdominal pain
• Ascites, or an abnormal buildup of fluid in the abdomen
• A mass in the abdomen
• Problems with bowel function
• Weight loss

In severe cases of the disease, the following signs and symptoms may be present:

• Blood clots in the veins, which may cause thrombophlebitis
• Disseminated intravascular coagulation, a disorder causing severe bleeding in many body organs
• Jaundice, or yellowing of the eyes and skin
• Low blood sugar level
• Pleural effusion
• Pulmonary emboli, or blood clots in the arteries of the lungs
• Severe ascites

A mesothelioma does not usually spread to the bone, brain, or adrenal glands. Pleural tumors are usually found only on one side of the lungs.

Mesothelioma is a form of cancer that is almost always caused by exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. At some point in our lives, nearly all of us have been exposed to asbestos in the air we breathe and the water we drink; from natural deposits in the earth, and from the deterioration of asbestos products around us. Most of us, however, do not become ill as a result of our exposure.Its most common site is the pleura (outer lining of the lungs and internal chest wall), but it may also occur in the peritoneum (the lining of the abdominal cavity), the heart, the pericardium (a sac that surrounds the heart) or tunica vaginalis.
More commonly, those who at some point are diagnosed with asbestos disease, have worked in jobs where more substantial exposure occurred over longer periods of time. Nevertheless, cases of mesothelioma have been documented as the result of lesser exposure, affecting family members of workers who came into contact with asbestos and brought it home on their clothing, skin or hair, or affecting those who lived in close proximity to asbestos manufacturing facilities. Symptoms of asbestos disease usually are not be apparent until decades after exposure.

Asbestos was used commercially in North America as early as the late 1800s, but its use increased dramatically during the World War II era when shipyards produced massive numbers of ships for the war effort. Since that time, asbestos-containing products were used by the construction and building trades, the automotive industry and the manufacturing industry. All told, more than 5,000 products contained asbestos.

For more than 50 years, products containing asbestos remained unregulated, and the manufacturers of those products continued to prosper, knowing full well that many of the millions of workers who came into contact with their products would ultimately suffer as the result of their actions. Finally, in the late 1970s, the Consumer Products Safety Commission banned the use of asbestos in wallboard patching compounds and artificial ash for gas fireplaces because the fiber could easily be released during use. In 1989, the Environmental Protection Agency banned all new use of asbestos, but uses established prior to that time were still allowed. Although awareness of the dangers of asbestos and public concern over the issue have led to a decline in domestic consumption over the years, a total ban on asbestos has not come to fruition. Asbestos is still imported, still used and still dangerous.

Although it is suggested that the number of mesothelioma cases in the U.S. has reached its peak and has begun to drop, a forecast released by the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER), in April, 2003, projected the total number of American male mesothelioma cases from 2003-2054 to be approximately 71,000. This number, however, does not take into consideration events such as the World Trade Center disaster on September 11, 2001, when millions of New Yorkers were potentially exposed to air filled with carcinogenic asbestos particles. The incidence of mesothelioma cases by state and county are shown in these tables. When the latency period for asbestos disease is factored in, cases of mesothelioma will continue to be diagnosed for years to come. See our page on mesothelioma risk factors.

Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or they have been exposed to asbestos dust and fiber in other ways. It has also been suggested that washing the clothes of a family member who worked with asbestos can put a person at risk for developing mesothelioma. Unlike lung cancer, there is no association between mesothelioma and smoking, but smoking greatly increases risk of other asbestos-induced cancer.^[3] Compensation via asbestos funds or lawsuits is an important issue in mesothelioma